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Abstract. A deeper understanding of biological mechanisms to promote more
efficient treatment strategies in proton therapy demands advances in preclinical
radiation research. However this is often limited by insufficient availability of
adequate infrastructures for precision image guided small animal proton irradiation.
The project SIRMIO aims at filling this gap by developing a portable image-guided
research platform for small animal irradiation, to be used at clinical facilities and
allowing for a precision similar to a clinical treatment, when scaled down to the
small animal size. This work investigates the achievable dosimetric properties of
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different lowest energy clinical proton therapy beams, manipulated by a dedicated
portable beamline including active focusing after initial beam energy degradation
and collimation.
By measuring the lateral beam size in air close to the beam nozzle exit and the
laterally integrated depth dose in water, an analytical beam model based on the
beam parameters of the clinical beam at the Rinecker Proton Therapy Center
was created for the lowest available clinical beam energy. The same approach
was then applied to estimate the lowest energy beam model of different proton
therapy facilities, Paul Scherrer Institute, Centre Antoine Lacassagne, Trento
Proton Therapy Centre and the Danish Centre for Particle Therapy, based on
their available beam commissioning data. This comparison indicated similar beam
properties for all investigated sites, with emittance values of a few tens of mm·mrad.
Finally, starting from these beam models, we simulated propagation through a
novel beamline designed to manipulate the beam energy and size for precise small
animal irradiation, and evaluated the resulting dosimetric properties in water. For
all investigated initial clinical beams, similar dosimetric results suitable for small
animal irradiation were found.
This work supports the feasibility of the proposed SIRMIO beamline, promising
suitable beam characteristics to allow for precise preclinical irradiation at clinical
treatment facilities.
This is the version of the article before peer review or editing, as submitted to
Physics in Medicine and Biology. IOP Publishing Ltd is not responsible for any errors
or omissions in this version of the manuscript or any version derived from it. The
Version of Record is available online at https://doi.org/10.1088/1361-6560/abc832
1. Introduction
Radiation therapy with protons or light ions offers the potential for higher dose
conformity compared to the more established photon therapy (Suit et al. 1982).
While the technological progress over the last decades has increased the accuracy
in proton therapy by enabling the delivery of highly conformal dose distributions
making use of intensity modulated proton beams (Liu et al. 2012), the biological
effects of radiation on the microenvironment of healthy and tumour tissues are not
yet completely understood (Durante 2014).
Preclinical in vivo experiments are expected to help elucidating those open questions.
While research platforms for image-guided small animal irradiation with photons are
commercially available (e.g. the Small Animal Radiation Research Platform SARRP,
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Verhaegen et al. (2018)), similar systems are rare for proton beams. Although small
animal irradiation with protons has already been performed without image guidance
at research accelerators (e.g. Greubel et al. (2011)) and at clinical facilities (e.g.
Müller et al. (2019), Bijl et al. (2002), Takata et al. (2015), Kondo et al. (2015),
Moyers et al. (2007)), it is difficult to provide the desired small lateral beam size and
precision in depth. More recently, Ford et al. (2017) and Kim et al. (2019) presented
set-ups for small animal irradiation using the on-board X-ray cone beam computed
tomography (CT) of the SARRP for image guidance. While the cyclotron used by
Ford et al is capable of delivering beam energies lower than clinical ones, Kim et
al used a cyclotron delivering clinical proton beam energies only down to 70 MeV.
Therefore, a range shifter at the end of the beamline is used to degrade the beam
energy to be suitable for small animal irradiation. In both cases, beam sizes suitable
for small animal irradiation are achieved using a collimation system in close vicinity
of the small animal. Also using a passive beam degradation and collimation system,
in Beyreuther et al. (2018) a set-up for in vitro experiments dedicated to research in
radiation biology is presented, which was subsequently extended to allow for in vivo
studies.
The project SIRMIO (Small Animal Proton Irradiator for Research in Molecular
Image-guided Radiation-Oncology, Parodi et al. (2019)) aims at building a portable
image-guided irradiation platform for precise small animal irradiation to be used at
different clinical proton therapy centres. In terms of image-guidance, the foreseen
set-up includes proton transmission imaging and ultrasonic tumor localization for
treatment planning and position verification along with on site range verification
using ionoacoustics and positron-emission-tomography. This work aims to investigate
the achievable dosimetric properties of a proposed new beamline concept which
combines a movable degrader and collimator with active magnetic focusing (hereafter
referred to as active beamline). To this end, a method to derive an analytical beam
model from experimental data is used. Applying this method, beam models are
obtained using experimental data of gantries and fixed beamlines from different
clinical facilities to serve as input for beamline transport studies for SIRMIO. The
necessary data are acquired in experiments at the Rinecker Proton Therapy Center
(RPTC, gantry) in Munich in the scope of this work. Additionally, commissioning
data are provided by the Paul Scherrer Institute (PSI, gantry), Centre Antoine
Lacassagne (CAL, gantry), Trento Proton Therapy Centre (APSS, fixed beamline)
and the Danish Centre for Particle Therapy (DCPT, gantry). We focus on these
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cyclotron- and synchrocyclotron-based facilities of different type and vendors as
they typically exhibit higher beam intensity and a broader energy spectrum than
lowest energie beams produced by synchrotrons (e. g. the Heidelberger Ionenstrahl-
Therapiezentrum, Parodi et al. (2012)). The dosimetric evaluation of the beams
manipulated by the proposed active beamline demonstrates the ability to produce
beam energies and sizes which can allow for precise small animal irradiation. It is
expected that the active beamline benefits from advantages in terms of entrance-
to-peak dose ratio and transmission compared to a purely passive design, besides
avoiding to place highly activated material (e.g. collimators) and producing
substantial neutron background in proximity to the biological target, as examined in
Parodi et al. (2019).
2. Materials and methods
2.1. Analytical model of the beam phase space
For a realistic simulation of a proton beam travelling through an active beamline, an
appropriate description of the incoming clinical beam is necessary. An analytical
beam model for beams with Gaussian spatial and momentum distribution is
explained in this section, following the approach given in Hinterberger (2008),
Wiedemann (1993) and Carey (1987). The method solely relies on easily measurable
dosimetric quantities - the lateral beam size at several positions in air and the
laterally integrated depth dose (IDD) in water, along with the knowledge of the
approximate initial beam energy. This makes the method being employable at any
clinical facility and is here applied to experimental data acquired in this work at the
RPTC as well as to similar data shared by different proton therapy centres. The
modelling explained below can be separated in two parts: the spatial and angular
distribution as well as the energy distribution. The complete analytical modelling is
described in more detail in the Appendix A.
2.1.1. Spatial and angular distribution The beam broadening in x-direction along
the propagation direction z can be described in terms of sigma by
σx(z) =
√
σ11(0) + 2z · σ12(0) + z2 · σ22(0). (1)
Thereby σ11(0), σ12(0) and σ22(0) are the beam parameters describing the variance
of the spatial and angular distributions and their correlation, respectively, at z = 0
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which corresponds to the position of the last element in the beamline. To determine
three unknowns, the beam sizes σx(z) need to be measured at least at three positions
z. However, knowledge of the sigmas at more positions along the beam propagation
direction reduces the uncertainties. The measured beam profiles include scattering
due to air which contributes to the broadening of the beam. This scattering is
assumed to induce a Gaussian lateral spread at different depths z of the beam with
the standard deviation σair(z), which is systematically removed from the measured
beam width σx,exp(z) by
σx(z) =
√
σx,exp(z)2 − σx,air(z)2. (2)
In this work, the contribution of scattering in air is extracted from a Geant4 MC
simulation (version 10.04.p02 Agostinelli et al. (2003)) of an infinitely narrow parallel
beam in air for each beam energy. More details on the influence of scattering in air
can be found in Appendix A.2. A fitting of the scatter-corrected beam sigmas σx(z)
according to equation 1 yields the beam parameters as the fit parameters. The




σ11σ22 − σ212. (3)
The determination of the beam parameters in y-direction works correspondingly.
Once the beam parameters are determined, they are used to sample horizontal and
vertical phase spaces from Gaussian density distributions. More information on the
modelling of the spatial and angular distribution is given in Appendix A.1.
2.1.2. Energy distribution The energy distribution of a clinical proton beam is
approximated by a Gaussian distribution. The mean energy E0 and the energy
spread σE0 is deduced from a measurement of the IDD in a medium, e.g. water.
Comparing the R80 position (R80 being the position of the dose fall-off to 80 %)
of the measured curve to the R80 value of a calculated beam with the approximate
mean energy (e.g. the nominal energy Enom which serves as an identifier for this
beam in the clinical workflow and approximates the mean energy), the mean energy








using p = 1.77 (Bortfeld 1997). The final energy spread at the Bragg peak σEf is
composed of two parts: the initial energy spread of the beam given by σE0 added up
quadratically to the energy straggling induced by the interaction of the protons with
the medium σES . To deduce the initial energy spread, a method developed by Bortfeld
(1997) and Grassberger et al. (2015) is adapted for this purpose and explained in more
detail in the appendix. A look up table is created with the peak widths R80− P80
(P80 being the position of the dose rise to 80 %) obtained from Geant4 simulations
of proton beams with the nominal energy of interest as mean energy E0 and different
initial energy spreads σE0 . The peak width in dependence of the energy spread is
fitted using a second order polynomial as implied in Bortfeld (1997). The measured
peak width is compared to the look up table and the corresponding energy spread can
be determined. The energy of a single particle is then sampled from a one-dimensional
Gaussian function with the determined mean energy E0 and energy spread σE0 . The
correlation between energy and other phase space coordinates cannot be determined
using this method, and is hence considered to be independent, which is a reasonable
assumption for clinical pencil beams. The method described in this section to deduce
the energy distribution of the beam is further explained in the Appendix A.3.
2.1.3. Validation and employment of the analytical beam model The developed
analytical beam model is validated by a Geant4 simulation, using the simulation
parameters given in the Appendix A.2. To assess the modelling of the spatial and
angular distribution, the sampled phase space is simulated from the position of the
nozzle exit z = 0 in air and evaluated at certain positions z downstream the nozzle,
which coincide with the positions of the measurement of the lateral beam profile.
Thus the simulated lateral beam width defined by the analytical beam model is
compared to the experimentally determined width. Additionally, the phase space is
simulated in water and the resulting IDD is compared to the experimental one to
validate the modelled energy spectra.
In a similar way, the phase space is employed for the assessment of the SIRMIO
beamline. The set-up described in section 3.3 is modelled in a Geant4 simulation
and the phase space representing the analytical beam model is propagated from the
position z = 0 mm, which is the position of the nozzle exit. After travelling through
the beamline, the beam propagates into a water phantom allowing for dosimetric
evaluation. This procedure enables the assessment of the proposed beamline with
respect to the validated and analytical beam model.
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2.2. Experimental characterization of the RPTC lowest energy clinical beam
Experiments were performed at the RPTC in Munich, Germany, at a beam
energy of 75 MeV and gantry angles 0◦ (vertical) and 90◦ (horizontal) in order
to obtain a beam model as explained in section 2.1. The isocentre is 725 mm
downstream of the last element in the beamline, which is the last multi strip
ionization chamber (MSIC) in air. This position z = 0 mm is named nozzle
exit. The lateral beam profiles are measured downstream the beam nozzle, for
a gantry angle of 0◦ at z = 305, 525, 725, 825, 925 mm and for a gantry angle
of 90◦ at z = 385, 485, 585, 725, 865, 1005 mm using a scintillation screen coupled
to a charge-coupled device (CCD, BIS2G,Wellhöfer-Scanditronix, nowadays IBA
Dosimetry, Schwarzenbruck, Germany) with a pixel size of 0.37 mm× 0.37 mm. For
0◦ gantry angle, the detector is placed directly on the patient table. For 90◦ gantry
angle, a special frame is used which is shown together with the detection system
in figure 1 a). The background signal is subtracted from the measured data and a
median filter with a kernel size of 3×3 pixels is applied to reduce signal enhancements
caused by random image noise (e.g. scattered neutrons). To determine the beam
sigmas, the transversal, two dimensional (2D) beam profile is laterally integrated in
x- and y-direction, to obtain a one dimensional (1D) profiles in y- and x-direction
with high statistics, respectively. Thereby x- and y-direction refer to the axes of the
room coordinate system, which are very slightly tilted against the major and minor
axes of the spatial beam ellipse for the considered beam energy. A single Gaussian
is fitted to the 1D profile, from which the standard deviation is obtained as beam
sigma in the corresponding direction.
To measure the IDD, a water phantom (PTW MP3-XS Phantom Tank, PTW -
Freiburg, Germany) is used, in which a parallel plate ionization chamber is inserted
on a motorized stage (PTW Bragg Peak Chamber 34070). In figure 1 b) the set-
up is shown. The measured data are corrected to account for the water equivalent
thickness (WET) of the entrance window of the Bragg peak chamber and the window
of the reference ionization chamber positioned at the entrance of the phantom, which
are 4.05 mm and 0.25 mm, respectively. The resolution in beam direction is 0.1 mm
in the Bragg peak region, defined by the step size of the moving ionization chamber.
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(a) (b)
Figure 1: a) Set-up for the detection of the lateral beam profile in air at RPTC with a
gantry angle of 90◦ using a scintillation detector. The detector is placed with a special
holder on the patient table. The last MSIC foil is visible in the beam nozzle. b)
Water phantom with an ionization chamber to measure the laterally integrated depth
dose profile of the beam at a gantry angle of 0◦. A holder for the potential placement
of a degrader is hanging from the nozzle (not used for the IDD measurement).
2.3. Characterization and comparison of different lowest energy clinical proton
beams
Beam characterization according to the analytical beam model described in section
2.1 is carried out for five European proton therapy facilities, which are briefly
introduced in the following. All facilities use a cyclotron or synchrocyclotron to
accelerate ions to the maximal available energy, along with a subsequently placed
degrader to reduce the beam energy. This procedure defines the lowest available
clinical beam energy, which is reported in this section. If in the clinical workflow
even lower beam energies are needed, the facilites are equipped with an additional
range shifter, which can be positioned in the nozzle close to the patient. The RPTC
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in Munich, Germany, was built by ACCEL (nowadays Varian Medical Systems, Inc.,
Palo Alto, California) and is equipped with a superconducting cyclotron accelerating
protons up to a nominal energy of 250 MeV. The degrader positioned behind the
cyclotron allows for clinically available beam energies ranging from 245 MeV to
75 MeV. The facility has four equivalent treatment rooms, each equipped with a
gantry including the one where beam characterization is done in this work, and
one fixed beam room initially foreseen for ocular treatment. The CAL in Nice,
France, hosts two protontherapy rooms. One room is dedicated to ocular treatments
and related to a dedicated 65 MeV cyclotron. The other room is a single room
solution with a gantry and the superconducting synchrocyclotron S2C2 developed
by IBA which provides protons accelerated up to 230 MeV. The lowest clinical beam
energy available with S2C2 at this facility is 100 MeV (Kleeven et al. 2013). A beam
model has been set-up for the gantry beamline in this study. Similar to the RPTC,
the PSI in Villingen, Switzerland, is equipped with a superconducting cyclotron
developed by ACCEL, capable of delivering protons with nominal energies ranging
from 70 MeV to 250 MeV. Besides one fixed beamline, three gantries are available,
two of which are in clinical use (PSI 2019) and one is dedicated to research. In
this study, a beam model is set-up for the beam exiting gantry 2. The APSS is
the proton therapy centre in Trento, Italy. The Proteus 235 cyclotron developed by
IBA delivers beam energies between 70 MeV and 228 MeV to two treatment rooms
equipped with a gantry and one fixed beamline, for which beam characterization is
performed (Tommasino et al. 2017). Finally, a model is developed for the proton
beam at the DCPT in Aarhus, Denmark, using data from the gantry, which is
equivalent to the beam transported by the fixed beamline. Acceleration is done with
a cyclotron provided by Varian delivering beam energies ranging from 70 MeV to
250 MeV. Additionally, three treatment rooms equipped with a gantry are available
for patient treatment (PTCOG 2019).
For the purpose of this study, in addition to own measurements performed at the
RPTC (section 2.2) experimental data were shared by the corresponding facilities.
These data included the IDD in water as well as the beam width in air at five
positions downstream the nozzle exit.
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2.4. In-silico dosimetric characterization of lowest energy clinical beams transported
by the SIRMIO beamline
The proton beam from a clinical facility has to be degraded in energy, collimated,
transported and refocused in order to meet the requirements of SIRMIO as a small
animal irradiation platform. To this end, several beamline options consisting of
degraders, collimators and a triplet of permanent magnet quadrupoles were simulated
in vacuum. In this work, the results obtained in a Geant4 simulation study using an
active beamline design (Kurichiyanil et al. 2019) sketched in figure 2 are presented
for all considered facilities. It includes a graphite degrader to obtain beams with
Figure 2: Schematic drawing of the active beamline consisting of a degrader
(graphite), a collimator (brass) and a triplet of permanent magnet quadrupoles
(NdFeB). The beam is entering from the nozzle, indicated with a blue arrow.
energies ranging from 20 to 60 MeV from a clinical beam. It is positioned 500 mm
downstream the nozzle exit. The nominal initial beam energies vary from 70 to
100 MeV, depending on the facility, as listed in table 1. A brass collimator of
40 mm thickness with a square opening of 1.2 mm × 1.2 mm scales the emittance of
the beam to match the acceptance of the subsequent triplet of permanent magnets.
The magnets are optimized in order to focus the range of beam energies to beam
sizes of 1.6 mm full width at half maximum (FWHM) at the focus. The position
of the magnets along the beam axis z is adjusted depending on the beam energy
being focused to keep the focal point at a fixed position. Not shown in the schematic
drawing is the water phantom with a size of 5 cm×5 cm×10 cm and a binning size of
50µm×50µm×50µm for the evaluation of dosimetric quantities in the simulations.
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It is positioned such that the focus of the manipulated proton beam coincides with
the Bragg peak location. From the simulated IDD, the entrance-to-peak ratio (EPR)








with Dentrance, Dpeak and Dtail being the laterally integrated dose at the entrance
of the water phantom, at the Bragg peak and at the dose tail (3 mm behind the
peak), respectively, each of those averaged in depth over five bins. Furthermore the
peak width (R80−P80) and the distal fall-off (R20−R80) of the IDD is calculated.
The FWHM and the lateral penumbra (lateral dose fall-off from 80 % to 20 %) are
calculated from the lateral beam profile at the focus.
3. Results
3.1. Experimental characterization of the RPTC lowest energy clinical beam
As an example, the lateral beam profile of the 75 MeV RPTC beam measured at the
isocentre (z = 725 mm) in air at a gantry angle of 0◦ is shown in figure 3a). Figure
3b) shows the profile data laterally integrated in y, along with the Gaussian fit. The
small spots of relatively high signal visible in figure 3a) are random image noise which
is being reduced by a median filter applied to the acquired data prior to the fitting
of the data with a Gaussian function. Especially at the centre of the distribution
the fit shows good agreement with the data, which leads to small uncertainties of
the beam sigma estimation. For both investigated gantry angles, the lateral beam
sigma in x- and y-direction is shown for all measured positions in figure 4a) and b),
respectively. The uncertainties resulting from the Gaussian fit of the lateral beam
profile are always smaller than 0.3 % and are too small to be visible in the plots. It
can be seen that the gantry angle has a clear influence on the beam size, resulting
in differences of 0.5 mm (in x- and y-direction) at the isocentre, while only a small
impact on the beam divergence.
The measured beam sigmas and the data after applying corrections for beam
broadening due to scattering in air are shown in figure 5 for the measurement at
a gantry angle of 0◦ degree. A fit using equation 1 is shown in the same figure
and the beam parameters resulting from the fit are given in table 1. These beam
parameters are used to model a phase space, from which protons are sampled
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(a) (b)
Figure 3: a) Experimentally determined two dimensional intensity profile in the
x/y plan of the proton beam at RPTC at the isocentre. b) In y-direction
laterally integrated profile at the isocentre. The green dots are the median filtered
experimental data, in red the Gaussian fit is shown.
(a) (b)
Figure 4: Lateral beam sigma of the proton beam measured at RPTC in a) x- and
b) y-direction along the beam propagation axis. The black squares correspond to
a gantry angle of 0◦, the red squares to gantry angle of 90◦. Uncertainties are too
small to be visible.
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(a) (b)
Figure 5: Illustration of the scattering correction applied to the measured data. The
black squares correspond to the experimentally determined beam size at a gantry
angle of 0◦ in a) x- and b) y-direction at five positions downstream the beam nozzle,
whose last element is located at 0 mm. The beam width corrected for scattering in
air is shown with red crosses, the dashed red line corresponds to the fit according to
equation 1.
and propagated through air and water to cross verify the beam profiles and IDD,
respectively, between experiment and simulation. The comparisons of the profiles
are shown in figure 6a) and 6b). Fitting errors are less than 0.3 % and not visible
in the figures. The analytical beam model reproduces the beam closely at every
evaluated position. The simulated and experimentally measured IDDs are compared
in figure 7. The error bars of the measured data points arise from the uncertainty
of the motor moving the ionization chamber (0.1 mm). The uncertainty of the dose
measurement is determined by the relative error between the dose measurement of
the reference ionization chamber and the Bragg peak chamber, which is considered to
be negligible. The R80 position and the peak width are determined to be 46.02 mm
and 1.96 mm, respectively. An uncertainty of 0.40 mm is chosen for the uncertainty of
the R80 position, as this is the allowed tolerance which was met in several preceding
measurements. Both profiles show overall good agreement with a difference in R80
position below 0.1 mm due to a small deviation in mean energy E0.
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(a) (b)
Figure 6: Lateral beam size of the proton beam at RPTC in a) x- and b) y-direction
at five positions downstream the nozzle exit. The black squares correspond to the
measured data at a gantry angle of 0◦. The red squares result from a Geant4
simulation using the analytical beam model.
(a) (b)
Figure 7: a) Normalized depth-dose profiles of the 75 MeV RPTC beam in water.
The black data points correspond to measured data with uncertainties, the red curve
corresponds to the simulation using the developed beam model. Due to the WET of
the ionization chamber and the reference chamber, the experimental data are only
visible for depths larger than 4.3 mm. For a better overview the dose fall-off to 80 % is
shown with a line marked by D80. In b) a zoom of the profiles is shown to emphasize
the agreement, along with the R80 position.
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3.2. Characterization and comparison of different lowest energy clinical proton
beams
Analytical beam models have been developed for all the investigated clinical beams,
using experimental data provided by the facilities. This includes IDDs as well
as beam widths in air at several positions downstream the nozzle, which suffered
scattering in air. For the beamline at the APSS, the mean energy and the energy
spread is taken from Tommasino et al. (2017) due to the too coarse resolution of
the available IDDs. For all other available beams, this information is determined
from the IDD as explained in section 2.1.2. The obtained model beam parameters
along with the mean energy and the energy spread are presented in table 1. The
given uncertainties arise from the analytical fitting procedure of the beam sigmas.
Additionally, the maximal available beam current at the isocentre is given for the
corresponding beam energy. For the RPTC 90◦ gantry angle (x-direction) and the
DCPT (y-direction) the available data are measured too far from the beam waist, and
therefore the fit function cannot describe the behaviour close to the nozzle. Therefore
the beam parameter σx(0) for RPTC and σy(0) for DCPT are set to be 2.5 mm and
2.8 mm, respectively, which allowed fitting of the data at other positions. The forcing
of the fit parameters in these cases leads to relatively high uncertainties of the beam
parameters. The values reported for the PSI gantry beamline refer a fully retracted
nozzle. The full extraction of the nozzle influences the beam parameters, leading to
a decrease in emittance of approx. 10 %. From the reported intensities, there is a
clear trend of larger beam currents at fixed beamlines than gantries. For example,
currents at the considered fixed beamlines can be up to 4.0 nA.
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Table 1: Beam parameters at the nozzle exits of the beams at the Rinecker Proton Therapy Center (RPTC),
Paul Scherrer Institute (PSI), Centre Antoine Lacassagne (CAL), Trento Proton Therapy Centre (APSS) and
the Danish Centre for Particle Therapy (DCPT). The beam parameters of the proton beam at the RPTC are
determined at 0◦ and 90◦ gantry angles. For RPTC, the required data were experimentally determined as
explained in section 2.2, for all other cases the data were shared by the corresponding facilities as discussed
in section 2.3.
1 Gantry 2 Fixed beamline ∗ Current at the fixed beamline
1RPTC - 0◦ 1RPTC - 90◦ 1CAL 1PSI 2APSS 1DCPT
Enom (MeV) 75 75 100 70 70 70
E0 (MeV) 75.32 100.45 71.16 68.5 71.41
σE0 (MeV) 0.58 0.83 0.55 0.48 0.88
σx (mm) 2.8(1) 2.5(2) 4.8(1) 4.0(1) 4.3(1) 4.2(5)
σxx′(mm·mrad) 1.9(2) 1.0(36) 5.4(3) 6.9(2) −6.9(13) −2.1(54)
σx′ (mrad) 6.2(1) 6.0(4) 5.5(1) 8.1(1) 4.8(1) 5.2(6)
εx (mm·mrad) 17.5(2) 14.8(18) 25.9(4) 18.0(6) 19.4(10) 21.6(38)
σy (mm) 3.6(1) 3.9(1) 4.2(1) 4.7(1) 2.0(3) 2.8(5)
σyy′(mm·mrad) −1.8(4) −1.6(1) 10.3(10) −0.6(2) −0.4(21) 3.0(62)
σy′ (mrad) 5.8(1) 6.0(1) 5.6(2) 8.4(1) 4.7(2) 5.0(7)
εy (mm·mrad) 20.4(1) 23.4(5) 21.2(11) 39.7(2) 9.3(16) 13.9(48)
Intensity (nA) 0.4 0.4 0.3 0.6 0.2 (4.0∗)
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From table 1 it is also evident that small differences in the beam sizes and
divergences are present between beams provided by different facilities. However,
an upstream collimator redefines the phasespace accepted by the beamline to the
central part of the beam phasespace. This is visualized in figure 8 in which the beam
ellipse of the RPTC beam is shown at the position of the collimator together with
the collimator acceptance. For this visualization, the beam model is propagated
analytically from the beam nozzle to the position of the collimator, contrary to
the simulation of the particles propagating from the nozzle through the SIRMIO
beamline, for which a Geant4 simulation is used as explained in section 2.4. Protons
which are not in the intersection of both areas, cannot travel through the collimator.
Therefore it can be concluded that the considered beams are suitable to be used with
the SIRMIO beamline, but with corresponding variation in transported fraction of
the beam. The phase space in figure 8 does not take into account the influence of the
degrader positioned upstream the collimator. However, it is located very close to the
collimator and therefore has a minor influence on the beam width at this position.
(a) (b)
Figure 8: Beam ellipse (black) of the RPTC beam in a) x- and b) y-direction at the
position of the collimator. The acceptance of the collimator is shown in magenta.
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3.3. In-silico dosimetric characterization of lowest energy clinical beams transported
by the SIRMIO beamline
The simulated IDDs of the clinical proton beams transported and manipulated by
the SIRMIO beamline in water are shown in figure 9 exemplarily for beam energies
degraded to 20 MeV and 50 MeV, starting from the modelled phase space of the
respective facilities at the initial proton beam energies of table 1. The Bragg peaks
(a) (b)
Figure 9: Geant4 simulated depth dose profiles in water of the a) 20 MeV and
b) 50 MeV proton beams obtained with the presented beamline, starting from the
analytical models of the lowest energy clinical beams at the corresponding colour-
coded facilities.
are located at 3.4 mm and 21.4 mm, respectively. Between the different simulated
clinical beams small deviations are observable, which result in an uncertainty of
±0.5 mm in range. To further evaluate and assess the longitudinal beam properties,
fundamental parameters (defined in section 2.2) are calculated and displayed in figure
10. In general, it is expected that beams which are subject to more degradation
show poorer performance than beams which experience less local degradation, as
this increases the energy spread. This can be seen in figure 10 in case of the CAL
beam with an initial energy of 100.45 MeV. The dose in the entrance region is higher
compared to the other beams, the peak width is larger and also the distal dose falls




Figure 10: a) Entrance-to-peak ratio, b) peak width (R80-P80), c) distal fall-off
(R20-R80) and d) tail-to-peak ratio of the energy degraded and actively focused
proton beams for four beam energies. The color code displayed in figure a) indicates
the facility of which the beam model was used as input file.
Likewise, the APSS beam (fixed experimental beamline) with the lowest initial beam
energy of 68.5 MeV and the smallest initial energy spread of 0.48 MeV leads to the
best results in terms of EPR, peak width, distal fall-off and TPR. When comparing
the beams with respect to their final energy, the EPR and the peak width is reduced
towards increasing energies.
The lateral dose profile in x-direction at the focus of the manipulated beams is
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shown in figure 11 for energies degraded to 20 MeV and 50 MeV. The corresponding
(a) (b)
Figure 11: Normalized lateral dose profiles of the manipulated beams degraded to
energies of a) 20 MeV and b) 50 MeV at the focus. The color code indicates the
facility of which the beam model was used as input file.
lateral penumbra and the FWHM are shown in figure 12 for both profiles in x-
and y-direction. For the profile in x-direction, the manipulated beams of 20 MeV
show differences up to 0.3 mm for the lateral penumbra and 0.7 mm for the FWHM,
depending on the incident clinical beam. For all other beam energies, only small
differences below 0.06 mm (lateral penumbra) and 0.3 mm (FWHM) are found. In
y-direction, differences up to 0.4 mm for the lateral penumbra and 1.0 mm for the
FWHM were observed for all the beam energies. All clinical beams show the smallest
lateral beam size when being degraded to 30 MeV. With values of approximately
0.5 mm and 0.7 mm, the APSS beam shows the smallest penumbra in x- and y-
direction, respectively, along with the smallest FWHM of 1.1 mm and 1.3 mm.
The energy spread of the manipulated beam is influenced by the extent of degradation
along with the initial energy spread. For further assessment, the energy spread
of the transported beam is extracted from the simulation and fitted with a single
Gaussian and the sigma σEf is extracted in dependence of the final beam energy and
the facility of which the beam model was used as input file. The result is shown
in figure 13. The influence of the degradation process on the final energy spread




Figure 12: Lateral penumbra (80 % to 20 %), top, in a) x- and b) y-direction along
with full width at half maximum (FWHM), bottom, in a) x- and b) y-direction of
the transported beams at the focus for four investigated beam energies. The color
code indicates the facility of which the beam model was used as input file.
beams. Differences in energy spread of the focused beams arising from differences
in initial beam energies and energy spreads are visible when degraded beams using
beam models of different facilities are examined, however, more studies are needed to
evaluate the dependency on the initial energy spread. This is particularly emphasized
for the comparison between CAL and APSS.
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Figure 13: Energy spread in terms of σEf of the manipulated beam after passing
the permanent magnet quadruplet for different final beam energies. The colorcode
indicates the facility of which the beam model was used as input file. Additionally,
the mean energy of the incoming clinical beam is given in brackets for the perspective
facility.
4. Discussion
The project SIRMIO aims at the development of a portable research platform
enabling precise and image-guided small animal irradiation at clinical facilities. This
demands the development of a beamline which is able to modify clinical proton
beams in energy and size for small animal irradiation. In this study, beam models of
five European facilities were created based on measured local beam characteristics
and transported through a novel beamline composed of degrading, collimating and
focusing elements in a simulation study. The results show overall similar properties of
the manipulated beams, which confirms the feasibility of a portable beamline concept.
The details of the beamline are still under optimization and will be reported in a
separate study together with the final assessment of the manipulated beam properties
for small animal irradiation in terms of treatment planning.
In the past five years, two systems were proposed for image-guided in-vivo research
in proton therapy by Ford et al. (2017) and Kim et al. (2019). Ford et al show in
a simulation study that the degradation of a 100 MeV to a 30 MeV beam with an
acrylic degrader results in an EPR larger than 50 %. In our study, this corresponds
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to the degradation of the beam at CAL showing an EPR of 61 % in agreement to the
findings of Ford et al. However, the EPR can be improved to less than 45 % for a
degraded beam of 30 MeV when using the clinical beam of the APSS with a nominal
initial energy of 70 MeV. Furthermore, in Ford et al measurements are performed
with beams of energies down to 30 MeV emerging from a cyclotron. The lateral beam
size is varied using collimators of different sizes, resulting in a typical penumbra of
0.8 mm. In this study the penumbra ranges from 0.5 mm to 2.0 mm, which is in good
agreement to the finding of Ford et al. Kim et al employ a clinical beam with an
initial energy ranging from 77 MeV to 98 MeV, hence a solid water plastic degrader of
constant thickness is used to scale down the beam energy as well as two collimators
are employed to reduce the lateral beam size. The energy of the beam from the
cyclotron is varied to yield manipulated beams of different ranges. For evaluation,
the ranges of the simulated beams of this study are calculated and compared to
the ranges of the beams presented in Kim et al. Best agreement was found for the
beams of 20 MeV and 77 MeV, 30 MeV and 80 MeV, 40 MeV and 85 MeV along with
50 MeV and 89 MeV (where for each pair the final energy of the SIRMIO beam is
given together with the initial beam energy in Kim et al). However, in all cases
the energy of the beam investigated in this study is lower than the energy of the
corresponding beam in Kim et al. This holds especially for the beam with the lowest
energy being 77 MeV (R90 = 5.96 mm) which is compared to the manipulated beam
of 20 MeV in this study (R90 = 3.52 mm). When choosing the fixed beam of the
APSS as initial beam, a significant improvement is found for all final beam energies
using the SIRMIO beamline with respect to the EPRs as defined in this study. As
the SIRMIO beamline makes use of the lowest available clinical beam energy and
varies the degrader thickness to yield different final beam energies, the amount of
degrader material passed by the beam is minimized. This results in a manipulated
beam with smaller energy spread, visible as a smaller EPR. For the beam of lowest
energy (corresponding to a final energy of 20 MeV in this study and an initial energy
of 77 MeV in the study of Kim et al) the IDDs show EPRs of 57 % and approx.
65 %, respectively, for the beam of highest energy (corresponding to a final energy
of 50 MeV along with a R90 of 21.46 mm in this study and an initial energy of
89 MeV along with a R90 of 21.68 mm in the study of Kim et al) EPRs of 27 % and
approximately 35 % are found, respectively. In Kim et al, the lateral beam shape
is modelled with a collimation system of different sizes. A beam width similar to
the beams in this study is found for a collimator size of 3 mm× 3 mm. Such set-up
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results in a beam width of approx. 2 mm FWHM, which is in between the findings
of this study with 1 mm to 3 mm FWHM. When comparing the presented active
beamline to the design of a purely passive beamline developed in the course of this
study (Parodi et al. 2019), advantages in transmission and a reduction of the neutron
fluence close to the target are found.
In the process of the SIRMIO beamline design, a challenge was found when aiming
simultaneously at a small spot size and a high transmission to guarantee suitable
treatment times. These goals are conflicting, as a closing of the collimator opening
to reduce the lateral beam size also reduces the particle fluence.
The next steps in this project will include the testing of the adapted clinical
beams in terms of treatment planning. Furthermore, possible advantages of an
additional range shifter behind the last element of the beamline are investigated
in an ongoing study. This is motivated by two findings of this work. Firstly,
the beamline presented in this study shows overall the best results for a beam
degraded down to 30 MeV. Besides degrading the beam even further upstream,
another option is to install a range shifter close to the focus. Secondly, preliminary
treatment plans have shown the possible necessity of beam energies below 20 MeV
for selected murine tumour indications (Kundel 2019). This issue can also be
addressed by the installation of an additional range shifter close to the target.
Also not discussed in this work is the activation of the beamline. Especially
for the portability of the beamline it is necessary that all components show low
activity after being irradiated. This requires the development of a proper shielding
system, which is being investigated in a separate study. A possible consequence
is a relatively heavy set-up that must be linked to facility-specific constraints on
the maximal permitted weight placeable in a treatment room. This favours the
installation of SIRMIO in fixed beamlines of experimental rooms. Additionally, fixed
beamlines typically show beam currents up to one order of magnitude higher than
delivered by a gantry. This applies not only to the few experimental fixed beamlines
considered in this study, where currents up to 4.0 nA (DCPT) were reported, but
also to dedicated ocular beamlines available e.g. at CAL, RPTC and PSI, where
also currents up to 4.0 nA can be expected. The SIRMIO set-up is especially
intended for the former experimental fixed beamlines, usually dedicated to quality
assurance and radiobiological experiments. The increased beam currents will be
beneficial to counteract beam losses in the dedicated SIRMIO beamline. Considering
future developments in relation to FLASH (Buonanno et al. 2019), (van de Water
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et al. 2019), beam currents are also expected to raise.
5. Conclusion
In this work, we demonstrated the capability of a proposed novel active beamline
to be used with proton beams from different proton therapy centres for producing
suitable beams for small animal irradiation. Analytical models of five clinical beams
were created and validated. In a simulation study, these beams were transported
through an active beamline leading to similar dosimetric results for all facilities.
Beam sizes suitable for a small animal treatment with similar precision as a clinical
treatment could be achieved. This paves the way for the realization of the project
SIRMIO, aiming at a portable installation which can manipulate different lowest
energy clinical beams for precise small animal irradiation.
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Appendix A. Analytical model of the beam phase space
The analytical beam model used for the description of clinical beams with Gaussian
spatial and momentum distribution is explained in this section in more detail,
following the approach given in Hinterberger (2008), Wiedemann (1993) and Carey
(1987).
Appendix A.1. Spatial and angular distribution
In this derivation, the horizontal and vertical motions are considered to be decoupled,
which allows treating the respective phase spaces independently from each other.
Although the derivation of the spatial and angular beam properties is done for mono-
energetic beams, it is valid for beams with small energy spread, such as usually
observed for clinical proton beams.
A particle beam can be represented by an ensemble of points in the six-dimensional
phase space, which is described by a density distribution ρ (x, y, x′, y′, z, E)
(Hinterberger 2008). For example the horizontal phase-space spanned by the position
(x) and divergence (x′) of the particles is considered for the derivation. This approach
is equally applicable to the vertical phase space (y,y′). Most density distributions
can be surrounded by an ellipse in phase space (Hinterberger 2008), described by
xᵀσx
−1x = 1, (A.1)
where xᵀ = (x, x′) is the beam vector pointing from the origin of the coordinate






, σ21 = σ12 (A.2)
is positive definite and symmetric, and its components σ11, σ22 and σ12 are the
variance of the spatial and angular distributions and their correlation, respectively.
When using other definition of beam parameters as e.g. the doubled spatial variance,
doubled covariance and doubled angular variance (Safai et al. 2008), care must be
taken in conversion. Following Liouville’s theorem, the area of the beam ellipse stays
constant when the beam is transported through systems described by conservative
forces (e.g. electromagnetic). The conserved area is known as beam emittance ε and





σ11σ22 − σ212. (A.3)
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Assuming a Gaussian distribution of the beam intensity, the density function is












The density distribution is characterised by elliptic isoprobability contours. The
beam ellipse defined in equation A.1 is the contour, in which the density is reduced
to a factor of exp (−1/2) compared to the maximum density at the centre of the
distribution. The maximal extension of the beam ellipse is given by one standard
deviation of the spatial and the angular distributions of the particles. In x-direction,






The correlation between σx and σx′
σxx′ = σ12 (A.6)
describes the orientation of the elliptical axes. The case of σ12 < 0 corresponds to
a focusing beam and σ12 > 0 corresponds to a diverging beam. The location of the
minimal lateral beam width is called beam waist.
The transformation of the beam parameters from an initial position z = 0 to any
other position z, where z is the axis of beam propagation, is described by the action
of the transfer matrix R as
σx(z) = Rx(z)σx(0)Rx(z)
ᵀ (A.7)
(Penner 1961). The transfer matrixRx(z) is found by solving the equations of motion
for the elements in the beamline. For the purpose of this work, the relevant part
is the beam propagating downstream from the last element of the beamline. To







is thus sufficient. The influence of scattering in air is considered in a separate
Monte Carlo study, as explained in section Appendix A.2. Solving equation A.7





σ11(0) + 2z · σ12(0) + z2 · σ22(0), (A.9)
where σ11(0), σ12(0) and σ22(0) are the beam parameters at z = 0 mm. To determine
three unknowns, the beam sizes need to be measured at least at three positions.
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However, knowledge of the sigmas at more positions along the beam propagation
direction reduces the uncertainties. A fitting of these data according to equation
A.9 yields the beam parameters as the fit parameters. Once the beam parameters
are determined, they are used to sample horizontal and vertical phase spaces from
respective multivariate Gaussian density function given by equation A.4.
Appendix A.2. Modelling of the scattering in air
The measured beam profiles include scattering due to air which contributes to the
broadening of the beam. This scattering contribution has to be systematically
removed from the measured beam profiles in order to correctly estimate the beam
sigmas at the nozzle exit. This scattering is assumed to induce a Gaussian lateral
spread at different depths z of the beam with the standard deviation σair(z). The




σx,exp(z)2 − σx,air(z)2. (A.10)
As an example, using Highland’s formula (Highland 1975) the influence of scattering
in air can be estimated to introduce a beam broadening of σx,air(z) = 1.5 mm at
the isocentre of the RPTC set-up. In this work, the contribution of scattering in
air is extracted from a MC simulation of an infinitely narrow parallel beam in air
for each beam energy. The simulation toolkit Geant4 (version 10.04.p02 Agostinelli
et al. (2003)) is used with the physics models being the ones from the reference
physics list QGSP BIC HP but replacing the default emstandard opt3 with the more
accurate emstandard opt4 for the modeling of electromagnetic physics, along with
an air density of 0.001 204 79 g/cm3 and an ionization potential of 85.7 eV (Berger
et al. 1984). This approach is more accurate than using Highland’s formula since
the latter takes into account only the Gaussian part of multiple Coulomb scattering
and therefore neglects other contributions to the lateral spreading of a beam such as
large angle scattered protons caused by interactions with nuclei (Pedroni et al. 2005)
which influence the fitting of a single Gaussian function to the data.
Appendix A.3. Energy distribution
In this work, the modelling of clinical beams with Gaussian energy distribution is
considered. The mean energy E0 and the energy spread σE0 is deduced from a
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measurement of the IDD in a medium, e.g. water. The IDD is measured for a
clinical beam with a certain nominal energy Enom, which labels this beam in the
clinical workflow and approximates the mean energy of the beam. To determine the




is used with R0 being the range in the medium. The parameters α and p depend
on the absorbing medium and the energy, respectively (Newhauser & Zhang 2015).
Comparing the R80 position (R80 being the position of the dose fall-off to 80 %)
of the measured curve to the R80 value of a calculated beam with the approximate
mean energy (e.g. the nominal energy) and an arbitrary energy spread (on which
the R80 value does not depend (Schuemann et al. 2014)), the mean energy of the







using p = 1.77 (Bortfeld 1997).
The correlation between IDD and energy spread is more complex. Proton dose
calculation algorithms typically rely on Monte Carlo simulations of the beam nozzle
and measured IDD curves (Hong et al. 1996), (Würl et al. 2016). However, a simpler
and faster analytical model developed by Bortfeld (1997) and further investigated
by Grassberger et al. (2015) was adopted for this purpose. The final energy spread
at the Bragg peak σEf is composed of two parts: the initial energy spread of the
beam given by σE0 added up quadratically to the energy straggling induced by the




+ σ2E0 . (A.13)
The polynomial relationship between range and energy given in equation A.11 is used
for the translation of the standard deviation of the energy to the standard deviation
of the range straggling. To describe the range straggling caused by the initial energy
spread of the beam, equation A.11 is linearized around E0. This is valid under the
assumption that the initial energy spread is small compared to the mean energy, i.















with σRS being the standard deviation of the range for a mono-energetic beam.
A look up table is created with the peak widths R80− P80 (P80 being the position
of the dose rise to 80 %) obtained from simulations of proton beams with the nominal
energy of interest as mean energy E0 and different initial energy spreads σE0 . Only the
P80 value depends on the energy spread, however peak width are reported to make
this method robust against small changes in mean energy. The simulation toolkit
Geant4 is used with the water density set to be 0.997 77 g/cm3 (corresponding to
a room temperature of 22◦ degree) and an ionization potential of 78.0 eV (Seltzer
et al. 2014). The nominal energies of interest are 70, 75 and 100 MeV in this work,
corresponding to the lowest clinical beam energies at the considered facilities. The
simulated initial energy spreads range from 0.0 to 1.2 MeV in steps of 0.2 MeV
in order to cover expected energy spreads in a clinical beam. The peak width in
dependence of the energy spread is fitted using a second order polynomial as implied
by equation A.14. The measured peak width is compared to the look up table with
simulated peak widths and the corresponding energy spread can be determined. The
energy of a single particle is then sampled from a one-dimensional Gaussian function
with the determined mean energy E0 and energy spread σE0 . The correlation between
energy and other phase space coordinates cannot be determined using this method,
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Pedroni, E., Scheib, S., Böhringer, T., Coray, A., Grossmann, M., Lin, S. & Lomax, A. (2005).
Experimental characterization and physical modelling of the dose distribution of scanned
proton pencil beams, Physics in Medicine & Biology 50(3): 541.
Penner, S. (1961). Calculations of Properties of Magnetic Deflection Systems, Review of Scientific
Instruments 32(2): 150–160.
PSI (2019). https://www.psi.ch/de/protontherapy/protonentherapie-am-psi.
PTCOG (2019). Facilities in Operation, https://www.ptcog.ch/index.php/facilities-in-operation.
Safai, S., Bortfeld, T. & Engelsman, M. (2008). Comparison between the lateral penumbra of a
collimated double-scattered beam and uncollimated scanning beam in proton radiotherapy,
Physics in Medicine and Biology 53(6): 1729–1750.
Schuemann, J., Dowdell, S., Grassberger, C., Min, C. H. & Paganetti, H. (2014). Site-specific range
uncertainties caused by dose calculation algorithms for proton therapy, Physics in Medicine
and Biology 59(15): 4007–4031.
Seltzer, S. M., Fernandez-Varea, J. M., Andreo, P., Bergstrom, P. M. J., Burns, D. T.,
Krajcar Bronic, I., Ross, C. K. & Salvat, F. (2014). Report 90: Key data for ionizing-
radiation dosimetry: Measurement standards and applications, Journal of the International
Commission on Radiation Units and Measurements 14(1): 1–110.
Suit, H., Phil, D., Goitein, M., Munzenrider, J., Verhey, L., Blitzer, P., Gragoudas, E., Koehler,
A., Urie, M., Gentry, R., Shipley, W., Urano, M., Duttenhaver, J. & Wagner, M. (1982).
Evaluation of the clinical applicability of proton beams in definitive fractionated radiation
therapy, International Journal of Radiation Oncology*Biology*Physics 8(12): 2199–2205.
Takata, T., Kondo, N., Sakurai, Y., Tanaka, H., Hasegawa, T., Kume, K. & Suzuki, M. (2015).
Reprint of Localized dose delivering by ion beam irradiation for experimental trial of
establishing brain necrosis model, Applied Radiation and Isotopes 106: 104–106.
Tommasino, F., Rovituso, M., Fabiano, S., Piffer, S., Manea, C., Lorentini, S., Lanzone, S., Wang,
Z., Pasini, M., Burger, W., La Tessa, C., Scifoni, E., Schwarz, M. & Durante, M. (2017).
Proton beam characterization in the experimental room of the Trento Proton Therapy
facility, Nuclear Instruments and Methods in Physics Research Section A: Accelerators,
Spectrometers, Detectors and Associated Equipment 869: 15–20.
van de Water, S., Safai, S., Schippers, J. M., Weber, D. C. & Lomax, A. J. (2019). Towards
34
FLASH proton therapy: The impact of treatment planning and machine characteristics on
achievable dose rates, Acta Oncologica 58(10): 1463–1469.
Verhaegen, F., Dubois, L., Gianolini, S., Hill, M. A., Karger, C. P., Lauber, K., Prise, K. M.,
Sarrut, D., Thorwarth, D., Vanhove, C., Vojnovic, B., Weersink, R., Wilkens, J. J. & Georg,
D. (2018). ESTRO ACROP: Technology for precision small animal radiotherapy research:
Optimal use and challenges, Radiotherapy and Oncology 126(3): 471–478.
Wiedemann, H. (1993). Particle Accelerator Physics, Springer Berlin Heidelberg.
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